Herbal medicine plus antivirals to prevent liver cancer in hepatitis B cirrhosis
Part of Cancer, Digestive system, Infections clinical trials.
This trial is testing whether adding a Chinese herbal medicine called Fufang Biejiaruangan to standard antiviral therapy can lower the chance of developing liver cancer in people with hepatitis B-related cirrhosis. If you are at higher risk for liver cancer, this combination might help prevent it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 65 years
- Diagnosed with cirrhosis caused by hepatitis B
- Your doctor confirms a specific Traditional Chinese Medicine pattern: Qi-zhi-xue-yu (a type of qi stagnation and blood stasis)
- A risk score (called aMAP) above 60, meaning you are at higher risk for liver cancer
- No prior diagnosis or treatment for liver cancer or other cancers
- Not pregnant or breastfeeding, and no other serious liver diseases (like hepatitis C, HIV, or alcohol-related liver disease)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a Chinese herbal medicine called Biejia-Ruangan Compound can help people with early-stage liver cancer who have already had successful treatment (surgery or ablation) live longer and keep the cancer from coming back. It is for people who also have chronic hepatitis B.
This study tests whether an herbal capsule (Babao Dan) combined with standard antiviral therapy can help prevent liver cancer in people with cirrhosis caused by hepatitis B. It aims to see if adding this traditional Chinese medicine reduces the chance of developing liver cancer.
This trial tests a medication (pegylated interferon alfa-2b) for people with hepatitis B-related liver cancer that has been completely removed by surgery or ablation. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial tests a combination of two drugs: tislelizumab (an immunotherapy that helps your immune system attack cancer) and huaier granule (a traditional Chinese medicine extract). It is for people with advanced liver cancer that cannot be removed by surgery and who have not had other systemic treatments before.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.